HP-β-CD (Synonyms: (2-Hydroxypropyl)-β-cyclodextrin)

Name: HP-β-CD
Brand: MedChemExpress
SKU: HY-101103
Rating: 5.0 (17 reviews)

Cat. No.: HY-101103 Purity: 99.74%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

HP-β-CD ((2-Hydroxypropyl)-β-cyclodextrin) is a widely used drug delivery vehicle to improve the stability and bioavailability.

For research use only. We do not sell to patients.

HP-β-CD Chemical Structure

CAS No. : 128446-35-5

Size	Price	Stock	Quantity
Free Sample (0.1 - 0.5 mg)		Apply Now
500 mg	USD 50	In-stock	Estimated Time of Arrival: December 31
1 g	USD 60	In-stock	Estimated Time of Arrival: December 31
5 g	USD 84	In-stock	Estimated Time of Arrival: December 31
10 g	USD 108	In-stock	Estimated Time of Arrival: December 31
50 g		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 17 publication(s) in Google Scholar

17 Publications Citing Use of MCE HP-β-CD

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Protocol
Purity & Documentation
References
Customer Review

Description

HP-β-CD ((2-Hydroxypropyl)-β-cyclodextrin) is a widely used drug delivery vehicle to improve the stability and bioavailability.

In Vitro

Cell treatment with HP-β-CD results in the activation of the transcription factor EB, a master regulator of lysosomal function and autophagy, and in enhancement of the cellular autophagic clearance capacity^[1]. HP-β-CD treatment reduces intracellular cholesterol resulting in significant leukemic cell growth inhibition through G2/M cell-cycle arrest and apoptosis. The IC₅₀ values for HP-β-CD after 72 hours exposure are in the range of 3.86-10.09 mM. HP-β-CD also shows anticancer effects against CML cells expressing a T315I BCR-ABL mutation (that confers resistance to most ABL tyrosine kinase inhibitors), and hypoxia-adapted CML cells that have characteristics of leukemic stem cells. In addition, colony forming ability of human primary AML and CML cells is inhibited by HP-β-CD^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

In Vivo

HP-β-CD administration promotes transcription factor EB-mediated clearance of proteolipid aggregates that accumulate due to inefficient activity of the lysosome-autophagy system in cells derived from a patient with a lysosomal storage disorder^[1]. Intraperitoneal injection of HP-β-CD significantly improves survival in leukemia mouse models. Systemic administration of HP-β-CD to mice has no significant adverse effects^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

CAS No.

128446-35-5

Appearance

Solid

Color

White to off-white

SMILES

CO[C@@H]1[C@H](O[R])[C@@H](O)[C@H](C)[C@@H](CO[R])O1.[C;D2]CC(O)C.[R].[7].[R=H or]

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Solvent & Solubility

In Vitro:

DMSO : 50 mg/mL (Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

H₂O : 50 mg/mL (Need ultrasonic)

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL; Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

For the following dissolution methods, please prepare the working solution directly. It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: PBS
Solubility: 100 mg/mL; Clear solution; Need ultrasonic and warming and heat to 60°C
Protocol 2

Add each solvent one by one: Saline
Solubility: 200 mg/mL; Clear solution; Need ultrasonic

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Calculation results:

Working solution concentration: mg/mL

This product has good water solubility, please refer to the measured solubility data in water/PBS/Saline for details.

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only.If necessary, please contact MedChemExpress (MCE).

Purity & Documentation

Purity: 99.74%

Select Batch:

Data Sheet (275 KB) SDS (393 KB)

COA (248 KB) HNMR (276 KB)

Handling Instructions (2659 KB)

References

[1]. Song W, et al. 2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. J Biol Chem. 2014 Apr 4;289(14):10211-22. [Content Brief]

[2]. Yokoo M, et al. 2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS One. 2015 Nov 4;10(11):e0141946. [Content Brief]

Cell Assay	Cells are incubated with HP-β-CD at various concentrations (5, 7.5, 10, 15, 20 mM) for 72 hours. Cell viability is assessed using a trypan blue dye exclusion method and cell proliferation is evaluated using a modified methyl-thiazol-diphenyl- tetrazolium (MTT) assay^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Animal Administration ^[2]	Mice: Mice are intraperitoneally injected with 200 μL vehicle (saline) or (2-Hydroxypropyl)-β-cyclodextrin (50 or 150 mM) for 20 consecutive days 3 days after transplantation, and survival is monitored daily. Leukemic cell engraftment is confirmed by detection of GFP-positive cells in the recipient’s BM using flow cytometry^[2]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
References	[1]. Song W, et al. 2-Hydroxypropyl-β-cyclodextrin promotes transcription factor EB-mediated activation of autophagy: implications for therapy. J Biol Chem. 2014 Apr 4;289(14):10211-22. [Content Brief] [2]. Yokoo M, et al. 2-Hydroxypropyl-β-Cyclodextrin Acts as a Novel Anticancer Agent. PLoS One. 2015 Nov 4;10(11):e0141946. [Content Brief]

HP-β-CD Related Classifications

Help & FAQs

Do most proteins show cross-species activity?
Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

HP-β-CD128446-35-5(2-Hydroxypropyl)-β-cyclodextrinBiochemical Assay ReagentsInhibitorinhibitorinhibit

Your Recently Viewed Products:

Product Name

Salutation

Applicant Name *

Email Address *

Phone Number *

Organization Name *

Department *

Requested quantity *

Country or Region *

Remarks

Product Name

Lot #

Applicant Name *

Email Address *

Phone Number

Department *

Organization Name *

Country or Region *

Remarks

Name
Email *

	Sorry, but the email address you supplied was invalid.

HP-β-CD (Synonyms: (2-Hydroxypropyl)-β-cyclodextrin)

Customer Review

HP-β-CD Related Antibodies

17 Publications Citing Use of MCE HP-β-CD

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity

Protocol

Purity & Documentation

References

Customer Review

HP-β-CD Related Antibodies

Molarity Calculator

Dilution Calculator

HP-β-CD Related Classifications

Keywords:

Your Recently Viewed Products:

Customer Review

Request for HNMR Report

SAFETY DATA SHEET (SDS)

Request for HNMR Report